Cadrenal Therapeutics, Inc. Common Stock (CVKD) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Cadrenal Therapeutics, Inc. Common Stock (CVKD)

View Full Profile →

Intrinsic Value

DCF Not Suitable for CVKD

Market cap ($0.02B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.

Alternative Approach:

Use relative valuation (P/E, P/S) vs. peer group.

Frequently Asked Questions

Is CVKD stock undervalued or overvalued?

Insufficient data to compute DCF valuation for CVKD. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is CVKD's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is CVKD's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For CVKD, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.